GleamWall
中文EN

ORMP ORAMED PHARMACEUTICALS INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1176309 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY435.3%
TTM EPS YoY412.5%
Revenue 3-yr CAGR-11.9%
Net income 3-yr CAGR—

Margins

Gross margin0.7%
Operating margin-754.4%
Net margin3,202.5%
FCF margin-457.7%
EBITDA margin-748.4%

Returns

ROE37.0%
ROA33.2%
ROIC (approx.)-10.4%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets13.5%
Debt / equity0.00x
Current ratio6.98x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.14x
Accruals ratio37.9%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-08-31
Income statement
Revenue$2.00M—$1.34M$2.70M$2.70M
Cost of revenue$1.99M————
Gross profit$13,000————
R&D expense$6.38M$6.32M$8.97M$27.64M$20.99M
SG&A expense$8.72M$6.46M$8.43M$13.81M$5.94M
Operating income-$15.09M-$12.78M-$15.77M-$40.60M-$24.22M
Interest expense—$853,000$2.04M——
Pretax income$75.32M-$15.92M$5.09M-$37.66M$5.31M
Income tax$11.31M$3.18M—$100,000—
Net income$64.05M-$19.06M$5.09M-$36.56M-$22.99M
EBITDA-$14.97M-$12.59M-$15.57M-$40.54M-$24.15M
EPS (basic)1.53-0.480.14-0.940.78
EPS (diluted)1.50-0.480.14-0.940.78
Dividends declared per share0.25————
Weighted avg. shares (diluted)42.42M40.85M40.57M39.00M28.47M
Balance sheet
Cash & equivalents$45.95M$54.42M$9.05M$40.46M$77.25M
Short-term investments$5.42M$3.44M$57.71M$3.74M$5.85M
Current assets$133.27M$143.22M$162.58M$157.11M$95.34M
PP&E, net$586,000$698,000$873,000$815,000$397,000
Total assets$230.86M$155.28M$220.55M$161.64M$128.00M
Current liabilities$19.09M$5.68M$53.21M$5.75M$6.68M
Short-term debt——$51.01M——
Long-term debt———$25,000$12.54M
Total debt———$25,000$12.54M
Total liabilities$31.12M$9.93M$57.66M$10.49M$11.48M
Shareholders' equity$199.74M$146.26M$163.82M$151.81M$115.77M
Net debt———-$40.44M-$64.70M
Shares outstanding39.28M39.92M40.34M39.56M35.29M
Cash flow statement
Operating cash flow-$9.14M-$8.41M-$10.29M-$27.92M-$21.18M
Capital expenditure$9,000$18,000$254,000$496,000$375,000
Free cash flow-$9.15M-$8.43M-$10.55M-$28.41M-$21.56M
Investing cash flow$5.44M$105.82M-$73.04M$30.21M-$23.76M
Financing cash flow-$4.74M-$52.04M$51.98M$10.78M$102.89M
Depreciation & amortization$121,000$193,000$196,000$58,000$77,000
Stock-based compensation$5.99M$4.05M$4.21M$11.51M$2.69M
Share buybacks$4.74M$2.48M———

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.